[1]Word Health Organization. Guidelines for the programmatic management of drug-resistent tuberculosis. Geneva: WHO, 2006: 5-18.[2]高官聚, 吴树才, 池跃朋. 耐药结核病的发生发展及控制展望. 河北医药, 2009, 31(10):1246-1248.[3]唐神结, 肖和平. 严重耐多药结核病的成因与对策[J/CD]. 中华临床医师杂志: 电子版,2009,3(3):62-66 [2011-01-28].http:∥www.cqvip.com/Read/Read.aspx?id=29807489.[4]张丽, 黄汉平, 张茜. 广泛耐药肺结核患者临床分析. 临床医学, 2010, 30(3): 22-24.[5]World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008.Geneva: World Health Organization, 2008.[6]Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med, 2010,181(1): 80-86.[7]Choi JH, Lee KW, Kang HR, et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest, 2010, 137(2): 393-400.[8]Brown TJ,Herrera-Leon L,Anthony RM,et al. The use of macroarrays for the identification of MDR Mycobacterium tuberculosis. J Microbiol Methods, 2006, 65(2): 294-300.[9]俞学锋, 钟利. 结核分枝杆菌耐药机制研究进展. 西南军医, 2010, 12(1): 125-127.[10]吴长东, 袁俐. 耐药结核病的分子生物学研究进展. 中国病原生物学杂志, 2009, 4(12): 943-945.[11]杨松, 张耀亭. 结核病耐药的分子机制及其防治研究进展. 临床肺科杂志, 2006, 11(5): 632-633.[12]Morris S, Bai GH, Suffys P, et a1. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis, 1995, 171(4): 954-960.[13]Kim BJ, Lee KH, Park BN, et a1. Detection of rifampin-resistant Mycobacterium tuberculosis in sputa by nested PCR—linked single-strand conformation polymorphism and DNA sequencing.J Clin Microbiol, 2001, 39(7): 2610-2617.[14]Abal AT, Ahmad S, Mokaddas E. Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. Microb Drug Resist, 2002, 8(2): 99-105.[15]王巍, 李洪敏, 吴雪琼, 等. 结核分支杆菌五种耐药基因检测的临床应用及评价. 中华结核和呼吸杂志, 2002, 25(11): 670-673.[16]Williams DL, Spring L, Gillis TP, et al. Evaluation of polymerase chain reaction-based universal heteroduplex generator assay for direct detection of rifampin susceptibility of Mycobacterium tuberculosis from sputum specimens. Clin Infect Dis, 1998, 26(2): 446-450.[17]Thomas GA, Williams DL, Soper SA. Capillary electrophoresis-based heteroduplex analysis with a universal heteroduplex generator for detection of point mutations associated with rifampin resistance in tuberculosis. Clin Chem, 2001, 47(7): 1195-1203.[18]Nachamkin I, Kang C, Weinstein MP. Detection of resistance to isoniazid, rifampin, and streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods. Clin Infect Dis, 1997, 24(5): 894-900.[19]Victor TC, van Helden PD, Warren R. Prediction of drug resistance in M. tuberculosis: molecular mechanisms, tools, and applications. IUBMB Life, 2002, 53(4-5): 231-237.[20]Makinen J, Marttila HJ, Marjamaki M, et al. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol, 2006, 44(2): 350-352.[21]Ling DI, Zwerling AA, Pai M. Geno type MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J, 2008, 32(5): 1165-1174. |